Table 1 Comparisons of patient characteristics between those treated with brolucizmab and photodynamic therapy as second-line treatments
Characteristic | Brolucizmab, N = 22 | Photodynamic therapy, N = 24 | P-values |
|---|---|---|---|
Age (years) | 76.6 ± 6.8; 78.0 | 74.7 ± 8.2; 76.0 | 0.415 |
Female | 4 (18.2%) | 4 (16.7%) | 0.890 |
Total number of previous injections | 22.6 ± 14.6; 20.0 | 11.9 ± 6.9; 11.0 | 0.009 |
BCVA (logMAR) | 0.48 ± 0.52; 0.35 | 0.30 ± 0.33; 0.30 | 0.314 |
SRF | 18 (81.8%) | 23 (95.8%) | 0.149 |
IRF | 13 (59.1%) | 7 (29.2%) | 0.044 |
CVH | 18 (81.8%) | 16 (66.7%) | 0.253 |
The maximum PED size (μm) | 423.1 ± 240.4; 405.5 | 422.3 ± 280.2; 330.0 | 0.750 |
SRH | 8 (36.4%) | 8 (33.3%) | 0.831 |
Fibrotic scar | 11 (50.0%) | 8 (33.3%) | 0.261 |
CCT (μm) | 216.0 ± 143.8; 152.5 | 244.4 ± 77.1; 234.5 | 0.113 |
CMT (μm) | 331.7 ± 110.9; 304.5 | 389.1 ± 174.2; 343.0 | 0.202 |
The mean of previous treatment intervals (weeks) | 7.6 ± 3.1; 7.7 | 6.4 ± 2.3; 5.7 | 0.319 |